Case: Patents/Generic Drugs (Fed. Cir.)

The Federal Circuit affirmed the district of New Jersey’s delisting order in Amneal Pharms. of N.Y. LLC’s action alleging that Teva Branded Pharm. Prods. R&D Inc. improperly listed inhaler patents in the Orange Book and delayed the entry of generic products onto the market. The appeals court affirmed the district court’s decision ordering Teva to delist its patents from the Orange Book on the ground that the patents contain no claim for the active ingredient at issue, albuterol sulfate, but instead are directed to components of a metered inhaler device.